A single dialysis session of hemodiafiltration with sorbent-regenerated endogenous ultrafiltrate reinfusion (HFR) removes hepcidin more efficiently than bicarbonate hemodialysis: a new approach to containing hepcidin burden in dialysis patients?

J Nephrol. 2018 Apr;31(2):297-306. doi: 10.1007/s40620-017-0383-0. Epub 2017 Mar 28.

Abstract

Background: Most hemodialysis patients have high Hepcidin-25 levels, which may be involved in the pathogenesis of several uremic complications related to an altered iron biology. The hemodialysis procedure itself can influence Hepcidin-25 levels by removing Hepcidin-25 and maybe stimulating its production due to a pro-inflammatory effect.

Methods: To assess the relationship between dialysis-related inflammation and intradialysis changes in Hepcidin-25, we performed a crossover trial in 28 hemodialysis patients to compare the effects on serum levels of Hepcidin-25 and inflammatory markers activated during dialysis [Tumor Necrosis Factor-α (TNF-α), Interleukin-6, C-reactive protein (CRP), Pentraxin-3] of a single dialysis session using a technique capable of reducing inflammation, HFR (Hemo Filtrate Reinfusion: a hemodiafiltration system combining convection, diffusion and adsorption) or bicarbonate-dialysis using either the same low-flux membrane as in the diffusion stage of HFR (LFBD) or a high-flux membrane (HFBD).

Results: HFR achieved a greater reduction in Hepcidin-25 levels than both LFBD [-72% (95% CI: -11 to -133), p = 0.022] and HFBD [-137% (95% CI: -2 to -272), p = 0.047], conceivably due to both a greater removal (because of its convective/adsorptive component) and a lower inflammation-related Hepcidin-25 production. HFR also led to a greater decrease in TNF-α than LFBD [-277% (95% CI: -59 to -494), p = 0.014], while the two methods induced similar changes in Interleukin-6, CRP and Pentraxin-3 levels.

Conclusions: Our findings suggest that a single bicarbonate-dialysis session can upregulate Hepcidin-25 synthesis and that HFR can fully overcome this effect, enabling a greater Hepcidin-25 removal during dialysis. Adequately-designed studies are needed, however, to establish whether the beneficial effect of HFR emerging from our study could reduce Hepcidin-25 (and TNF-α) burden and improve clinically-relevant outcomes.

Trial registration: ISRCTN15957905.

Keywords: Bicarbonate-dialysis; Hemo Filtrate Reinfusion (HFR); Hepcidin-25; Pro-inflammatory cytokines.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Bicarbonates*
  • C-Reactive Protein / metabolism
  • Cross-Over Studies
  • Female
  • Hemodiafiltration / adverse effects
  • Hemodiafiltration / instrumentation
  • Hemodiafiltration / methods*
  • Hemodialysis Solutions
  • Hepcidins / blood*
  • Humans
  • Inflammation / blood
  • Inflammation / etiology
  • Interleukin-6 / blood
  • Male
  • Middle Aged
  • Serum Amyloid P-Component / metabolism
  • Tumor Necrosis Factor-alpha / blood

Substances

  • Bicarbonates
  • Hemodialysis Solutions
  • Hepcidins
  • IL6 protein, human
  • Interleukin-6
  • Serum Amyloid P-Component
  • Tumor Necrosis Factor-alpha
  • hepcidin 25, human
  • PTX3 protein
  • C-Reactive Protein